Vivo Capital’s Immunic IMUX Stock Holding History

Vivo Capital’s Portfolio IMUX Stock Details IMUX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-63,218	Closed	-$1.59M	–	54
2023 Q2	$1.59M	Hold	63,218	–	–	0.11%	44
2023 Q1	$942K	Hold	63,218	–	–	0.07%	44
2022 Q4	$833K	Buy	+63,218	New	+$1.72M	0.1%	45

Other funds holding IMUX

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Gratus Capital Atlanta, Georgia $2.5B AUM 32.89% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

PHP

Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Vivo Capital's IMUX Position: Q3 2023 in Review

Vivo Capital sold out of Immunic (IMUX) in Q3 2023, closing a stake of 63,218 shares — an estimated $1.59M sold.

Vivo Capital first reported a position in IMUX in Q4 2022 and held it in 3 quarters. The position peaked at $1.59M in Q2 2023. 53 funds tracked by Wall St. Rank hold IMUX as of Q3 2023.

Vivo Capital reported no remaining Immunic position as of Q3 2023 after selling out during the quarter.
Vivo Capital sold 63,218 Immunic shares in Q3 2023, an estimated $1.59M.
Vivo Capital first reported a position in Immunic in Q4 2022 and held it in 3 quarters.
Vivo Capital's Immunic position peaked at $1.59M in Q2 2023.
53 funds tracked by Wall St. Rank held Immunic as of Q3 2023.

Based on Vivo Capital's 13F filing for Q3 2023, filed 8 Nov 2023.